CareDx Inc (CDNA)vsNatera Inc (NTRA)
CDNA
CareDx Inc
$63.68
+3.76%
HEALTHCARE · Cap: $3.17B
NTRA
Natera Inc
$412.56
+0.92%
HEALTHCARE · Cap: $53.25B
Smart Verdict
WallStSmart Research — data-driven comparison
Natera Inc generates 491% more annual revenue ($2.71B vs $458.09M). CDNA leads profitability with a 24.2% profit margin vs -7.1%. CDNA earns a higher WallStSmart Score of 53/100 (C-).
CDNA
Buy53
out of 100
Grade: C-
NTRA
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+68.0%
Fair Value
$61.69
Current Price
$63.68
$1.99 discount
Intrinsic value data unavailable for NTRA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 52.2% year-over-year
Conservative balance sheet, low leverage
Keeps 24 of every $100 in revenue as profit
Revenue surging 37.7% year-over-year
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
0.0% earnings growth
Operating margin of 0.2%
ROE of -2.6% — below average capital efficiency
0.0% earnings growth
Weak financial health signals
Trading at 32.5x book value
ROE of -10.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CDNA
The strongest argument for CDNA centers on Revenue Growth, Debt/Equity, Profit Margin. Profitability is solid with margins at 24.2% and operating margin at 0.2%. Revenue growth of 52.2% demonstrates continued momentum.
Bull Case : NTRA
The strongest argument for NTRA centers on Revenue Growth, Market Cap, Debt/Equity. Revenue growth of 37.7% demonstrates continued momentum.
Bear Case : CDNA
The primary concerns for CDNA are P/E Ratio, EPS Growth, Operating Margin.
Bear Case : NTRA
The primary concerns for NTRA are EPS Growth, Piotroski F-Score, Price/Book.
Key Dynamics to Monitor
CDNA profiles as a growth stock while NTRA is a hypergrowth play — different risk/reward profiles.
CDNA carries more volatility with a beta of 2.43 — expect wider price swings.
CDNA is growing revenue faster at 52.2% — sustainability is the question.
CDNA generates stronger free cash flow (29M), providing more financial flexibility.
Bottom Line
CDNA scores higher overall (53/100 vs 31/100), backed by strong 24.2% margins and 52.2% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CareDx Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
CareDx, Inc. discovers, develops and markets diagnostic solutions for transplant patients and caregivers globally. The company is headquartered in South San Francisco, California.
Natera Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Natera, Inc., a diagnostic company, develops and markets molecular testing services globally. The company is headquartered in San Carlos, California.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?